Mission Bio, a leader in single-cell multi-omics solutions, has completed an equity financing round led by Ally Bridge Group. The funding follows significant traction with biopharma customers and recent platform innovations.
Last month, Mission Bio launched its Single-Cell Targeted Genotype and Gene Expression assay, the first assay to simultaneously profile DNA and RNA from over 10,000 single cells. The company plans to expand this capability to tri-omics, allowing for the simultaneous profiling of DNA, RNA, and protein.
The funding will support three key initiatives:
— Commercial Expansion and Partnerships: Mission Bio will broaden its customer base to meet the growing demand from pharmaceutical companies developing cancer therapies.
— Development of Single-Cell Tri-omics Capabilities: The company will advance its platform to include targeted RNA analysis alongside its existing DNA and protein capabilities, enabling researchers to understand better how cancer therapies work and why resistance develops.
— Accelerated Clinical Adoption: Mission Bio will expand the platform’s use in various cancer segments, including multiple myeloma and CAR-T cell therapy applications. The platform’s ability to provide a comprehensive solution from sample to answer will help clinicians with personalized treatment guidance.
Mission Bio has also expanded its leadership team by appointing Matthew H. Cato as the new Chief Commercial Officer. Cato, who has been with the company since 2017, will help lead the company’s commercial expansion in the multi-omics space.
How the funding will be used: The new investment will be utilized to fund innovative developments, commercial partnerships, and the clinical adoption of its Tapestri Platform. The company’s goal is to accelerate the platform’s use in cancer treatment by providing crucial insights for making treatment decisions.
KEY QUOTES:
“This strong support from Ally Bridge Group and other investors validates our leadership position in single-cell multi-omics and enables us to take the next step in our mission of transforming precision medicine. We are now positioned to expand our commercial footprint while advancing our technology to address critical unmet needs in cancer research and treatment.”
Brian Kim, CEO
“Mission Bio’s single-cell tri-omics platform represents exactly the type of transformative life science innovation we seek to support. This investment reflects our continued conviction that Mission Bio’s technology will become essential infrastructure for precision medicine, particularly as the industry shifts toward more complex cell and gene therapies requiring comprehensive characterization at the individual cell level.”
Kevin Reilly, Managing Director at Ally Bridge Group
